Keros S, Heim J, Hakami W, Zohar‐Dayan E, Ben‐Zeev B, Grinspan Z, Kruer MC, Meredith AL. Lisdexamfetamine Therapy in Paroxysmal Non-kinesigenic Dyskinesia Associated with the
KCNMA1-N999S Variant.
Mov Disord Clin Pract 2022;
9:229-235. [PMID:
35141357 PMCID:
PMC8810426 DOI:
10.1002/mdc3.13394]
[Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2021] [Revised: 10/04/2021] [Accepted: 12/03/2021] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND
KCNMA1-linked channelopathy is a rare movement disorder first reported in 2005. Paroxysmal non-kinesigenic dyskinesia (PNKD) in KCNMA1-linked channelopathy is the most common symptom in patients harboring the KCNMA1-N999S mutation. PNKD episodes occur up to hundreds of times daily with significant morbidity and limited treatment options, often in the context of epilepsy.
CASES
We report 6 cases with the KCNMA1-N999S variant treated with lisdexamfetamine (0.7-1.25 mg/kg/day), a pro-drug of dextroamphetamine. Data were collected retrospectively from interviews and chart review. Parent-reported daily PNKD episode counts were reduced under treatment, ranging from a 10-fold decrease to complete resolution.
CONCLUSION
Our findings suggest that lisdexamfetamine is an effective therapy for PNKD3 (KCNMA1-associated PNKD). Treatment produced dramatic reductions in debilitating dyskinesia episodes, without provocation or exacerbation of other KCNMA1-associated symptoms such as seizures.
Collapse